Drowning morbidity · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drowning (fatal and non‐fatal) · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Unsafe water exposure · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of unintentional injury · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Program safety · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resolution of daytime urinary incontinence · children aged 6 to 12 years with overactive bladder with urge incontinence
It is very uncertain whether voiding education with uroflowmetry and feedback changes resolution of daytime urinary incontinence at 12 months after 6… compared with anticholinergics (very low certainty).
1 finding from 1 review
Cognitive function · people with Alzheimer's disease
2 findings from 1 review
Cognitive function · people with severe Alzheimer's disease
2 findings from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
Change in capacity for activities of daily living · people with severe Alzheimer's disease
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
Behavioural symptoms (change from baseline at 26 weeks measured using the NPI) · people with Alzheimer's disease
1 finding from 1 review
Acceptability · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of participants (change from baseline at 26 weeks) · people with Alzheimer's disease
1 finding from 1 review
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low